Welcome to our dedicated page for Aldeyra Therapeutics news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics stock.
Aldeyra Therapeutics develops investigational therapies for immune-mediated diseases, with news centered on its RASP modulator platform and late-stage ocular programs. Company updates commonly cover reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa; and next-generation RASP modulators including ADX-248 and ADX-246 for systemic and retinal immune-mediated diseases.
Recurring developments include FDA interactions on the reproxalap New Drug Application, clinical and preclinical results, pipeline prioritization, manufacturing and regulatory disclosures, and research-and-development presentations. Aldeyra also reports conference participation and corporate updates tied to its Nasdaq-listed biotechnology issuer profile.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aldeyra Therapeutics (NASDAQ: ALDX) has completed enrollment in its Phase 3 INVIGORATE-2 clinical trial for reproxalap, a new treatment for allergic conjunctivitis. This investigational drug aims to provide relief for patients who currently rely on therapies with limited effectiveness and significant side effects. The trial involved 131 patients exposed to allergens in a controlled environment, with primary results focusing on patient-reported ocular itching. Top-line results are expected in the first half of 2023. Reproxalap has shown positive results in previous trials, demonstrating significant improvement in symptoms. The drug represents a novel therapeutic approach, with over 2,300 patients studied and minimal safety concerns reported.
Aldeyra Therapeutics announced the enrollment of the first patient in a Phase 2 clinical trial for ADX-629, an oral drug targeting atopic dermatitis. This multicenter trial will assess ADX-629's safety and efficacy in adults with varying severity of the condition. In Part 1, 10 patients will receive the drug for 90 days, with top-line results expected in the second half of 2023. Atopic dermatitis impacts over 16.5 million adults in the U.S., and ADX-629 could become the first oral RASP modulator for this condition. The drug has shown potential in other trials for conditions like psoriasis and COVID-19. Alongside atopic dermatitis, ADX-629 is being evaluated for chronic cough, nephrotic syndrome, and Sjögren-Larsson Syndrome, with results from additional trials also anticipated this year.
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has completed enrollment for its Phase 2 clinical trial of ADX-629, an investigational RASP modulator for chronic cough treatment. The multicenter trial includes 51 patients with unexplained chronic cough, assessing safety as the primary endpoint, alongside secondary outcomes like cough frequency and quality of life. Top-line results are anticipated in the first half of 2023. ADX-629 aims to address a significant unmet medical need, with preliminary studies indicating elevated RASP levels in affected patients. The company's broader strategy involves developing therapies that modulate immune responses rather than targeting single proteins.